Tempus, Seidman Cancer Center team up for customized cancer treatment

Tempus and University Hospitals Seidman Cancer Center, part of the Case Comprehensive Cancer Center at Case Western Reserve University­, have formed a partnership to develop genomic data, advanced molecular analysis and clinical decision support tools with the goals of improving research and care.

Tempus will provide genomic and transcriptomic sequencing and analysis for ovarian and triple negative breast cancer patients, helping physicians identify treatments using bioinformatics and machine learning. UH Seidman Cancer Center, with a 120-bed cancer hospital, will dedicate treatments in more than 300 clinical studies for improved cancer treatment and prevention.

"Over the last couple of decades, technology has transformed much of our daily lives and it is time we bring these advances into the clinic," said Eric Lefkofsky, co-founder and CEO of Tempus. "As we work to modernize cancer care, we are proud to bring the Tempus operating system and analytics platform to UH Seidman Cancer Center, empowering its physicians to make data-driven decisions tailored to its patients."

"At UH Seidman Cancer Center, we are committed to innovation and staying on top of the latest treatment protocols and advanced decision-support tools that can assist our physicians," said Stanton L. Gerson, Director of UH Seidman Cancer Center. "We are pleased to partner with Tempus, a company that shares our commitment to innovation and bringing the power of technology into clinic."